A Profile of Repair Biotechnologies, Working to End Atherosclerosis

Repair Biotechnologies is the company I founded with Bill Cherman a few years ago, to work on interesting projects in the rejuvenation biotechnology space. Time flies when one is busy. Our primary focus these days is the development of what we call the cholesterol degrading platform (CDP), a technology that does exactly what one would expect from the name. Localized excesses of cholesterol - and particularly toxic, altered forms of cholesterol - lie at the root of numerous serious medical conditions, and contribute to a lesser degree to many more.

Of those conditions atherosclerosis is the most important, given the vast numbers of people it kills, year in and year out, and given the inability of present approaches to therapy to do more than slow down its progression. Our view of this sort of challenge in medicine is to take the direct path, treat excess cholesterol as a form of damage, and repair that damage by removing the cholesterol. In an animal model of atherosclerosis, the cholesterol degrading platform achieved a 48% reversal of arterial obstruction by plaque following a single treatment.

"All of the greatest research programs start out with one scientist poking at something that he or she finds interesting. In this case it was the question of why mammalian cells do not routinely break down cholesterol, and instead make do with an intricate, fragile set of processes for shuttling cholesterol within cells and throughout the body. The presence of localized excesses of cholesterol in blood vessel walls is a lifespan-limiting circumstance that occurs to all of us, leading to atherosclerosis, then rupture or blockage of blood vessels that causes a stroke, heart attack, and death. Why then, do none of the cells involved in blood vessel tissue and the immune response to atherosclerosis actively break down cholesterol, but rather engage a Rube Goldberg apparatus of moving cholesterol around to try to solve the problem? The reason why we have atherosclerosis in the first place is that this machinery fails the moment that the tissue environment departs from a youthful, undamaged ideal. It is not robust at all. A more direct approach is needed."

The core mechanisms of CDP came into being due to the academic curiosity of a few "visionary and talented researchers"; once a way to safely break down excess cholesterol in cells was found and optimised, the Strategies for Engineered Negligible Senescence (SENS) community, who are focused on producing effective treatments for aging and age-related disease, became aware of these mechanisms and worked on implementing CDP. "The scientists presented their data at the first Undoing Aging conference, and Aubrey de Grey of the SENS Research Foundation later made an introduction to Repair Biotechnologies. The SENS philosophy - and the Repair Biotechnologies philosophy - is to reverse age-related disease by repairing the damage that causes it. Excess cholesterol is clearly a form of damage. Removing it is a form of repair. CDP strikes at a root cause of atherosclerosis, and other conditions in which excess cholesterol drives pathology. That makes it very attractive to those of us who think of aging in terms of damage and think of rejuvenation in terms of repair."

CDP is a platform technology that seeks to solve the root cause of cholesterol build-up by degrading excess, non-essential cholesterol with an entirely new, target-specific, rate-limited pathway, which the process introduces into cells. "We introduce a de novo pathway for catabolism of excess cholesterol, breaking it down into a water-soluble catabolite that leaves cells and is removed from the body fairly rapidly. Introduced into mice, the CDP pathway is safe and well-tolerated. It does not interfere with the normal cholesterol metabolism required for cellular activities. It is a very attractive basis for therapy."

Link: https://www.longevity.technology/repair-bios-novel-platform-and-exclusive-from-ceo/


'... 48% reversal of arterial obstruction by plaque following a single treatment'

Way to go! Good luck and hopefully a short time to market.

Posted by: Jones at February 10th, 2021 6:00 AM

Nice preliminary results. Hope to see this soon in clinical trials. Heart disease is the leading cause of death in the world.

Posted by: Jonathan Weaver at February 10th, 2021 6:06 AM

Excellent work! Thanks!

Posted by: Neil at February 10th, 2021 9:57 AM

This looks very interesting. I am looking forward to learning what the technology actually is. I think your estimate of the market value of a successful treatment is low.

Posted by: JohnD at February 10th, 2021 11:02 AM

Hello Reason, awesome results on your very mew company, I wish very much quick success for your first project, it sounds astonishing.

Couple questions.

1. You just started this only a couple years ago, yet have what seems like incredibly successful for heart health. Why so quick where or more highly funded companies have not produced a potentially huge blockbuster product?

2. I thought Repair Biotechnologies was planning on working with the immunity system, specifically the thymus. Is this still the plan?

Congratulations again, Reason. You're my hero, more than sports figures, politicians, and movie stars. You're doing something for ALL of us!

Posted by: Robert C. at February 10th, 2021 11:22 AM

Wow. Faster please. And for the treatment 'shut up and take my money'

Posted by: Cuberat at February 10th, 2021 8:18 PM

Thanks for taking on this immense task. And thanks again for keeping this blog going. I hope that CDP works out. And I hope that Thymus regeneration works out too (with the ongoing COVID-19 epidemic and the constant daily meat grinder masacre of cancer humanity could really do with some immune system regeneration).

Posted by: jimofoz at February 11th, 2021 4:41 AM

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.